Solid-State Chemistry: A Technical Forum - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Solid-State Chemistry: A Technical Forum
Leading experts share insight on polymorphism and crystallization.


Pharmaceutical Technology
Volume 33, Issue 12, pp. 34-35, 65


Patricia Van Arnum
Understanding the solid-state properties of an active pharmaceutical ingredient (API) is critical in formulation development and a finished drug product. Patricia Van Arnum, senior editor, asked several leading experts to share their insight into this field: Menno A. Deij, head of technology development at Avantium Pharma (Amsterdam); Chris Frampton, chief scientific officer of SAFC Pharma's Pharmorphix Solid State Services (Cambridge, UK); and Noel Hamill, team leader in the physical sciences group at Almac (Craigavon, UK).

Crystal-structure prediction

PharmTech Can you outline the major issues involved in polymorphism and advances in crystal-structure prediction?

Deij: A lot of effort goes into understanding the crystalline solid phase of the API. The pharmaceutical industry is required to screen for polymorphism, that is, the ability of a molecule to exist as two or more crystalline phases that have different arrangements and/or conformations of the molecules in the crystal lattice (1). At room temperature, there is only one polymorph that fits the definition of the most stable; all other polymorphs are metastable and may convert to the most stable form (2). Properties that can differ among solid forms include color, melting point, spectral properties, solubility, crystal shape, water sorption and desorption properties, particle size, hardness, drying characteristics, flow and filterability, compressibility, and density. These variations can lead to differences in dissolution rate, oral absorption, bioavailability, toxicology and clinical results, hence both safety and efficacy are impacted (3, 4). The potential formation of multiple polymorphs of an API is particularly challenging when producing solid oral- dosage drug products. To make solid oral-dosage forms with crystalline APIs, pharmaceutical companies prefer to use the most stable polymorph to prevent the conversion to a less soluble polymorph, which can affect the efficacy of a drug product (5).

In an ongoing effort over the past 20 years, the academic community has pursued the prediction of crystal polymorphs starting from the molecular structure (6). Ideally, a researcher would like to search through the complete range of crystal structures and evaluate their free energies accurately as a function of temperature and pressure to obtain the global minimum energies of optimal crystal structures. The crystal-structure prediction process starts with the generation of millions of trial crystal structures, followed by the optimization of these structures and ranking according to their lattice energy as a first approximation to the lattice free energy. The crystal structure with the lowest lattice energy is expected to correspond to the most stable polymorph that can be found experimentally. The differences between the stable and metastable forms is typically on the order of only a few kJ/mol.

In the past, the lattice-energy ranking was based on molecular mechanics and generic forcefields. In this approach, molecules are modeled as balls and springs, representing the atoms and bonds. The forcefield is a large table that describes the balls' and springs' intramolecular behavior during bond stretching, bond bending, out-of-plane bending, and torsional rotation. The intermolecular interactions are described as charge–charge interactions and induced dipole–dipole interactions (van der Waals interactions). These forcefields are based on empirical data with fitted parameters. Forcefields are meant to be generic and able to describe a lot of different situations. Because the problem of crystal-structure prediction requires very accurate energy rankings, it turns out that the precision and accuracy of these forcefields is not sufficient.

The most recent developments, however, introduced by Marcus Neumann and his company, Avant-garde Materials Simulation, do not use generic forcefields. Advanced quantum-mechanical calculations (dispersion-corrected density functional theory or d-DFT) are used instead to develop a forcefield that is customized specifically for the molecule at hand (7, 8). This forcefield is then used in the geometry optimization of the thousands of crystal structures generated. The most promising structures with the lowest lattice energy are reranked with d-DFT, which results in an energy ranking that is of unprecedented accuracy and precision, giving the required confidence in the computational results.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
22%
Attracting a skilled workforce
30%
Obtaining/maintaining adequate financing
11%
Regulatory compliance
37%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here